echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Gan Lai announces that FXR agonist ASC42 has achieved good data in phase I clinical trials in the United States

    Gan Lai announces that FXR agonist ASC42 has achieved good data in phase I clinical trials in the United States

    • Last Update: 2021-06-28
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Gan Lai Pharmaceutical announced on the 16th that its non-alcoholic steatohepatitis drug candidate farnesol X receptor (FXR) agonist ASC42 has achieved good safety and pharmacodynamic biomarker top-line data in the Phase I clinical trial in the United States


    The Phase I trial of ASC42 in the United States is the first randomized, placebo-controlled, double-blind, single-dose and multiple-dose escalation and food-effect clinical trial conducted in humans


    Based on the animal models of non-alcoholic steatohepatitis in mice and rats, it is predicted that the therapeutic dose for humans is 15 mg once a day, each time


    Overall, ASC42 showed good safety and tolerability


    In addition, the test results show that high-fat meals have no significant effect on the pharmacokinetic parameters of ASC42


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.